DOCSLIB.ORG

Thermo Scientific Product Catalog

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Thermo Scientific Product Catalog Thermo Scientific Product Catalog Drugs of Abuse Testing, Drug Monitoring, Instrumentation, and Quality Control Products Contents Introduction Immunosuppressive Drug Management 4-7 The Value Of Innovation 30-31 Assays, Calibrators and Controls 8-9 One Resource: Multiple Technologies Instrumentation Drugs Of Abuse 41-45 Indiko Clinical and Specialty Chemistry Systems 12 CEDIA/DRI Urine Assays 45 Indiko Consumables 13 Indiko DAT Reagents Thermo Scientific MAS Controls 14-15 CEDIA Calibrators 48-51 Omni Consolidated Controls 16-17 DRI Calibrators 52-53 Serum Chemistries 18-19 CEDIA/DRI Controls 54-55 Urine Chemistries 19 MAS DOA Total Controls 56-57 Immunoassay 20 Instrument References 58 Cardiac and Diabetes 33-40 Oral Fluids Assays, Reagents, 59 Immunology and Protein Calibrators and Controls 60 Toxicology Specimen Validity Tests 61-63 Dimension Vista Controls 20-21 Assays, Reagents, Calibrators and Controls Thermo Scientific MAS Programs Endocrine 64-67 LabLink xL Quality Assurance Program 22-23 Assays, Reagents, Calibrators and Controls 68 Value Assignment Program Serum Toxicology Thermo Scientific MAS Control References 24-25 Assays, Reagents, Calibrators and Controls 70-74 Analytes Therapeutic Drug Monitoring 75-78 Instruments Experience our Quality 26-27 CEDIA and DRI Assays, Calibrators and Controls General Ordering Information 28-29 QMS Assays, Calibrators and Controls 79 To Place An Order Improve your results 79 Technical Service and Support The limitations of the RIA combined with continued This homogeneous enzyme immunoassay has innovation in biomedical research created the proven to be one of the important advancements perfect environment to take immunoassays in a in the evolution of immunoassays, enabling the new direction. The Enzyme Immunoassay (EIA) automation of the immunoassay test and facilitating and the Enzyme-Linked Immunosorbent Assay its transition from speciality laboratories to general (ELISA) were envisioned in the 1960s, but it took labs and clinical settings. Today CEDIA technology almost a decade for researchers to demonstrate is the platform supporting a broad menu of conclusively that the EIA/ELISA was the next step in immunoassays. building a new generation in immunoassays. These techniques replaced radioisotopes with enzymes in the labeling of antigens and antibodies which could Thermo Fisher Scientific continues to forge then be detected by spectrophotometric means. the way with new immunoassays for drugs The first tests were not as precise and sensitive of abuse screening and therapeutic drug as the RIA; however, improvements in techniques monitoring. accelerated during the 1970s. The full potential of the homogeneous enzyme Today Thermo Scientific™ CEDIA™ immunoassay is just beginning to be explored. technology is the platform supporting a Thermo Fisher Scientific continues to forge the way with new immunoassays for drugs of abuse broad menu of immunoassays for drugs screening and therapeutic drug monitoring that of abuse screening, therapeutic and provide customized solutions for large reference immunosuppressant drug monitoring and and hospital-based laboratories as well as a toxicology testing. growing list of non-traditional testing venues such as the workplace, government institutions, drug Cloned Enzyme Donor Immunoassay technology detection and treatment programs, and physician (CEDIA) was developed by Microgenics offices and clinics. The value of innovation (Thermo Fisher Scientific) in the early 1980s. An enduring history of serving science From routine chemistries to highly sensitive tests Researchers and clinicians worldwide soon that will enable the discovery of new biomarkers began to recognize the exciting potential of for disease diagnosis, the latest immunoassay this breakthrough technique and numerous techniques are built on the foundation of radio- laboratories were built and equipped to conduct immunoassay (RIA). This revolutionary concept tests that required the use of radioisotopes. As was developed for measurement of endogenous the technology was fine-tuned, RIAs for many plasma insulin by Solomon Berson and Rosalyn new analytes were published. Although the Yalow in 1959. Working together as a team, these RIA technique was valued for its sensitivity and two scientists proposed the use of the interaction specificity, there was growing concern about between antibodies and antigens to detect the workplace safety, the expense of the equipment presence or quantify the concentration of specific required for handling radioactive materials and the analytes in human body fluids. An isotope of a ability to properly dispose radioactive waste. radioactive element was used to label antibodies and antigens. 4 5 Around the world thousands of Thermo Scientific assays are loaded every day on a wide range of testing platforms. At Thermo Fisher Scientific, we have been at the forefront of enzyme-based turbidimetric immunoassay evolution for more than three decades. The spectrum of our integrated products and services offers both breadth and depth in the areas of drugs of abuse, specimen validity testing and toxicology testing; therapeutic and immunosuppressive drug monitoring; and quality control and data management. The synergy of multiple technologies, a robust menu of homogenous enzyme immunoassays optimized for most clinical chemistry analyzers and the global reach of our customer-responsive training and product support has made Thermo Scientific products the preferred resource for reference and hospital laboratories and other drug monitoring facilities. That’s why our research and development We never forget endeavors are driven by a sense of urgency and guided by the spirit of innovation. That behind every assay performed is a story Around the world thousands of Thermo Scientific During the mid 1990s, Thermo Fisher Scientific System (QMS). Our cutting edge Thermo assays are loaded every day on a wide range introduced its DRI™ product line. The marketplace Scientific™ QMS™ assays are the culmination of testing platforms. While we are proud of the reception to these liquid, ready-to-use assays of more than two decades of research and trust our customers have placed in us we never was unparalleled. Increased lab productivity, development in the application of microparticle lose sight of the fact that behind every assay low cost per test and short turnaround times technology to immunodiagnostics. performed is a story – men, women, and children without sacrificing precision, accuracy and The QMS method employs advanced particle facing challenges and uncertainty with hope for lot-to-lot consistency were right on target with technology to develop a wide range of particle- a healthier future. That’s why our research and clinical laboratory needs. More recently, we have enhanced turbidimetric immunoassays for use on development endeavors are driven by a sense of strengthened our technological leadership with automated chemistry analyzers. urgency and guided by the spirit of innovation. the introduction of the Quantitative Microsphere 6 7 One Resource Multiple Technologies CEDIA Thermo Scientific™ CEDIA™ method is a single phase, competitive binding process that combines analyte-specific antibodies and two genetically engineered fragments of the bacterial enzyme ß-galactosidase to accurately and reliably detect the Enzyme Acceptor (EA) presence of drugs and their metabolites as well as other substances in serum, plasma, whole blood, urine, and oral fluids. Genetic Enzyme Donor Enzyme Fragment (ED) Benefits Engineering Complementation • Guaranteed consistency: kit-to-kit, lot-to-lot, year-to-year • Accurate and specific results Active Enzyme Reconstituted Active Enzyme • Lower limits of detection of analytes in test matrix • Excellent low-end sensitivity and specificity Inactive Enzyme Fragments • Linear dose response curve • Urine, oral fluids, serum, plasma, and whole blood [ ] CEDIA Technology: genetic engineering of enzyme fragments. DRI Thermo Scientific™ DRI™ products are proven and trusted testing solutions that offer high analytical accuracy while eliminating time-consuming steps in reagent preparation. DRI technology is based on the competition between a drug or drug metabolite labeled with the enzyme glucose-6-phosphate + + dehydrogenase (G6PDH) and free drug from the sample for a fixed amount of specific antibody binding sites. In the absence of free drug from the sample, the specific antibody binds to the drug labeled with G6PDH. As a result, enzyme activity is inhibited. Enzyme-labeled Molecules Cofactor SUBSTRATE Benefits of the compound to be measured “NAD” “G6P” “ENZ-CONJUGATE” NADH • Applications for low, medium and high volume laboratories • Accurate and specific results DRI Technology • Assays optimized for most clinical chemistry analyzers • Excellent low-end sensitivity and specificity G6PDH in the presence of Cofactor and Substrate forms NADH. • Minimizes unnecessary confirmations • Guaranteed consistency: kit-to-kit, lot-to-lot, year-to-year The NADH absorbs light at 340 nm. + + QMS Thermo Scientific™ QMS™ (Quantitative Microsphere System) assays are particularly well suited to measuring therapeutic drugs in whole blood, serum or plasma. Antibody Free Drug Particle Bound Drug Our QMS two component assay system is based on the competitive inhibition immunoassay principle: If the drug targeted by the assay is present in the sample, these free drug molecules compete with a microparticle-bound drug in one reagent for a limited No Inhibition Partial Inhibition Complete
Load more

Recommended publications
  • First Xenon-Xenon Collisions in the Lhc
    9th International Particle Accelerator Conference IPAC2018, Vancouver, BC, Canada JACoW Publishing ISBN: 978-3-95450-184-7 doi:10.18429/JACoW-IPAC2018-MOPMF039 FIRST XENON-XENON COLLISIONS IN THE LHC M. Schaumann∗, R. Alemany-Fernandez, P. Baudrenghien, T. Bohl, C. Bracco, R. Bruce, N. Fuster-Martinez, M. A. Jebramcik, J.M. Jowett, T. Mertens, D. Mirarchi, S. Redaelli, B. Salvachua, M. Solfaroli, H. Timko, J. Wenninger, CERN, Geneva, Switzerland Abstract EXECUTION OF THE RUN In 2017, the CERN accelerator complex once again demonstrated its flexibility by producing beams of a new A total of about 18 h of LHC time were taken for the Xe ion species, xenon, that were successfully injected into LHC. collision run. The schedule was designed to include set-up, On 12 October, collisions of fully stripped xenon nuclei first injection, validation and physics data taking. A further 12 h were devoted to experiments on crystal collimation, de- were recorded for the first time in the LHC√ at a centre-of- scribed elsewhere [3]. This tight schedule was only feasible mass energy per colliding nucleon pair of sNN = 5.44 TeV. Physics data taking started 9.5hafter the first injection of by drastically reducing the complexity of the set-up follow- xenon beams and lasted a total of 6h. The integrated lumi- ing the model of the p–Pb pilot run in September 2012 [4,5] nosity delivered to the four LHC experiments was sufficient when first injection, validation and physics data-taking were that new physics results can be expected soon. We provide achieved within a single fill.
    [Show full text]
  • XENON X-1100 High-Intensity Pulsed Light System
    XENON X-1100 High-Intensity Pulsed Light System The low cost R&D tool for investigating the applicability of Pulsed Light for new and emerging applications. The tool that researchers, scientists and engineers have been looking for is here. An easy-to-use photonic system developed by XENON that will open new doors and lead to new discoveries. The power of Pulsed Light In virtually all disciplines of science and technology there are applications where precise delivery of energy is demanded. One less studied energy delivery mechanism is the use of high-intensity pulsed light. At present the most prevalent example of this is in the use of lasers. However, the point source, coherent and single wavelength nature of lasers, are often not suited to the majority of challenges facing many industries. In these situations, it is crucial to have a broad spectra source so as not to be restricted in choosing materials with specific absorption characteristics. Because XENON sources generate light which extends from the deep UV to IR and often with peak pulse powers measured in megawatts, the ability of these sources to perform tasks such as breaking chemical bonds, sintering, ablating or sterilizing is highly realizable. The high peak powers generated by XENON’s production level systems are possible by tightly controlling the pulse durations measured from a few microseconds to milliseconds. Until now there was no practical method of generating this intense pulsed light in a low-cost R&D tool that was safe, compact and versatile. XENON has developed a system to address this challenge based on over 50 years of exper- tise in the Pulsed Light industry.
    [Show full text]
  • Cytoscan Assay Manual Workflow User
    CytoScan™ Assay USER GUIDE Manual Workflow Catalog Numbers 901835, 901834, 901859, 901860 Publication Number 703038 Revision 7 For Research Use Only. Not for use in diagnostic procedures. The information in this guide is subject to change without notice. DISCLAIMER TO THE EXTENT ALLOWED BY LAW, LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) WILL NOT BE LIABLE FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING YOUR USE OF IT. Important Licensing Information This product may be covered by one or more Limited Use Label Licenses. By use of this product, you accept the terms and conditions of all applicable Limited Use Label Licenses. Corporate entity Life Technologies | Carlsbad, CA 92008 USA | Toll Free in USA 1 800 955 6288 TRADEMARKS All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. Microsoft, and Excel are either registered trademarks or trademarks of Microsoft Corporation in the United States and/or other countries. QIAGEN, Gentra and Puregene are registered trademarks of QIAGEN. Titanium is a trademark of Clontech Laboratories, Inc. Tough-Spots is a registered trademark of Diversified Biotech. ©2011, 2014, 2017 Thermo Fisher Scientific Inc. All rights reserved. Contents CHAPTER 1 Before you begin. 6 Introduction . 6 Assay warnings and precautions . 7 Genomic DNA general requirements and recommendations . 9 Sources of human genomic DNA . 10 Genomic DNA extraction/purification methods . 10 RNase treatment . 10 Controls . 10 Data analysis . 11 CHAPTER 2 CytoScan™ Assay procedure . 12 Temperature definitions . 12 Section 1: Prepare gDNA plate . 13 Dilute stock gDNA to working concentration .
    [Show full text]
  • Incoming Letter: QIAGEN N.V
    WACHTELL, LIPTON , ROSEN & KATZ MARTIN LIPTON STEVEN A. COHEN 51 W E S T 52N D S T R E E T DAVID E. SHAPIRO SABASTIAN V. NILES HERBERT M. WACHTELL DEBORAH L. PAUL DAMIAN G. DIDDEN ALISON ZIESKE PREISS THEODORE N. MIRVIS DAVID C. KARP NEW YORK, N.Y. 1 0 0 1 9 - 6 1 5 0 IAN B OC Z K O TIJANA J. DVORNIC EDWARD D. HERLIHY RICHARD K. KIM MATTHEW M. GUEST JENNA E. LEVINE DANIEL A. NEFF JOSHUA R. CAMMAKER TELEPHONE: (212) 403 -1000 DAVID E. KAHAN RYAN A. McLEOD ANDREW R. BROWNSTEIN MARK GORDON DAVID K. LAM ANITHA REDDY MARC WOLINSKY JOSEPH D. LARSON FACSIMILE: (212) 403 -2000 BENJAMIN M. ROTH JOHN L. ROBINSON STEVEN A. ROSENBLUM JEANNEMARIE O’BRIEN JOSHUA A. FELTMAN JOHN R. SOBOLEWSKI JOHN F. SAVARESE WAYNE M. CARLIN GEORGE A. KATZ (1965 -1 9 8 9) ELAINE P. GOLIN STEVEN WINTER SCOTT K. CHARLES STEPHEN R. D iPRIMA JAMES H. FOGELSON (1967 - 1 9 91) EMI L A. KLEINHAUS EMILY D. JOHNSON JODI J. SCHWARTZ NICHOLAS G. DEMMO LEONARD M. ROSEN (1965 - 2 0 14 ) KARESSA L. CAIN JACOB A. KLING ADAM O. EMMERICH IGOR KIRMAN RONALD C. CHEN RAAJ S. NARAYAN RALPH M. LEVENE JONATHAN M. MOSES OF C O UN S EL GORDON S. MOODIE VIKTOR SAPEZHNIKOV RICHARD G. MASON T. EIKO STANGE DONGJU SONG MICHAEL J. SCHOBEL MARTIN J.E. ARMS ERIC S. ROBINSON DAVID M. SILK JOHN F. LYNCH BRADLEY R. WILSON ELINA TETELBAUM MICHAEL H. BYOWITZ PATRICIA A. ROBINSON* ROBIN PANOVKA WILLIAM SAVITT GRAHAM W.
    [Show full text]
  • DCAT MEMBER COMPANY MEETING LOCATOR V. 4
    DCAT MEMBER COMPANY MEETING LOCATOR v. 4 THE BENJAMIN Sancilio Pharmaceuticals Company, Inc. Sri Krishna Pharmaceuticals Ltd. Amino Chemicals Ltd. Zydus Pharmaceuticals (USA) Inc. Apogee Pharma, Inc. C2 PHARMA INTERCONTINENTAL BARCLAY Calyx Chemicals & Pharmaceuticals Ltd. AbbVie* ChemCon GmbH ACIC Pharmaceuticals Inc. Concord Biotech Limited Advitech SA Dipharma Francis Srl Amneal Pharmaceuticals LLC DSM Sinochem Pharmaceuticals ALP Pharm F.I.S. - Fabbrica Italiana Sintetici S.p.A. AMRI Jost Chemical Co. Asymchem Inc. Jubilant Pharma Capsugel, Now a Lonza Company* PharmSource, A GlobalData Company CBC AMERICAS Corp. PolyPeptide Group CellMark USA, LLC ROHNER Inc. Charioteer Pharmaceutical Co., Ltd., Zhejiang FIFTY NYC, A AFFINA HOTEL Chemical and Pharmaceutical Solutions Chiral Quest Corp. Chartwell Pharmaceuticals, LLC Croda, Inc. HOTEL 48LEX DFE Pharma AB BioTechnologies, Inc. DPL-US AiPing Pharmaceutical, Inc. EQ Esteve Almac Evonik Corporation Aptuit LLC FAREVA SA AZAD Fine Chemicals Ltd. Flavine North America, Inc. Cambridge Isotope Laboratories, Inc. Formosa Laboratories, Inc. CMC Biologics Grifols International S.A. Groupe Parima Hainan Poly Pharm. Co., Ltd. Navin Fluorine International Limited Harris Pharmaceutical Qualicaps, Inc. Helm AG RC2 Pharma Connect LLC Hetero USA, Inc. Recipharm Hikal, Ltd. Recro Gainesville LLC Interchem Corporation Reed-Lane, Inc. Inventia Healthcare PVT LTD Please note: Some DCAT member companies have requested not to be listed in the locator. (*) indicates member companies with Business Meeting Spaces in more than one hotel. INTERCONTINENTAL BARCLAY CONT'D PiSA BioPharm, Inc. SPI Pharma Inc. Johnson Matthey Tapemark Kingchem Life Science LLC Unither Pharmaceutical Legacy Pharmaceutical Packaging Uquifa S.A. Lonza AG* Neuland Laboratories Ltd. LOTTE NY PALACE Orion Group AbbVie* Par Pharmaceutical, Inc.
    [Show full text]
  • Pharmacology – Inhalant Anesthetics
    Pharmacology- Inhalant Anesthetics Lyon Lee DVM PhD DACVA Introduction • Maintenance of general anesthesia is primarily carried out using inhalation anesthetics, although intravenous anesthetics may be used for short procedures. • Inhalation anesthetics provide quicker changes of anesthetic depth than injectable anesthetics, and reversal of central nervous depression is more readily achieved, explaining for its popularity in prolonged anesthesia (less risk of overdosing, less accumulation and quicker recovery) (see table 1) Table 1. Comparison of inhalant and injectable anesthetics Inhalant Technique Injectable Technique Expensive Equipment Cheap (needles, syringes) Patent Airway and high O2 Not necessarily Better control of anesthetic depth Once given, suffer the consequences Ease of elimination (ventilation) Only through metabolism & Excretion Pollution No • Commonly administered inhalant anesthetics include volatile liquids such as isoflurane, halothane, sevoflurane and desflurane, and inorganic gas, nitrous oxide (N2O). Except N2O, these volatile anesthetics are chemically ‘halogenated hydrocarbons’ and all are closely related. • Physical characteristics of volatile anesthetics govern their clinical effects and practicality associated with their use. Table 2. Physical characteristics of some volatile anesthetic agents. (MAC is for man) Name partition coefficient. boiling point MAC % blood /gas oil/gas (deg=C) Nitrous oxide 0.47 1.4 -89 105 Cyclopropane 0.55 11.5 -34 9.2 Halothane 2.4 220 50.2 0.75 Methoxyflurane 11.0 950 104.7 0.2 Enflurane 1.9 98 56.5 1.68 Isoflurane 1.4 97 48.5 1.15 Sevoflurane 0.6 53 58.5 2.5 Desflurane 0.42 18.7 25 5.72 Diethyl ether 12 65 34.6 1.92 Chloroform 8 400 61.2 0.77 Trichloroethylene 9 714 86.7 0.23 • The volatile anesthetics are administered as vapors after their evaporization in devices known as vaporizers.
    [Show full text]
  • Xenon Gas Xe Safety Data Sheet SDS P4677
    Xenon Safety Data Sheet P-4677 This SDS conforms to U.S. Code of Federal Regulations 29 CFR 1910.1200, Hazard Communication. Date of issue: 01/01/1979 Revision date: 10/24/2016 Supersedes: 10/02/2014 SECTION: 1. Product and company identification 1.1. Product identifier Product form : Substance Name : Xenon CAS No : 7440-63-3 Formula : Xe Other means of identification : Xenon 1.2. Relevant identified uses of the substance or mixture and uses advised against Use of the substance/mixture : Industrial use. Use as directed. 1.3. Details of the supplier of the safety data sheet Praxair, Inc. 10 Riverview Drive Danbury, CT 06810-6268 - USA T 1-800-772-9247 (1-800-PRAXAIR) - F 1-716-879-2146 www.praxair.com 1.4. Emergency telephone number Emergency number : Onsite Emergency: 1-800-645-4633 CHEMTREC, 24hr/day 7days/week — Within USA: 1-800-424-9300, Outside USA: 001-703-527-3887 (collect calls accepted, Contract 17729) SECTION 2: Hazard identification 2.1. Classification of the substance or mixture GHS-US classification Compressed gas H280 2.2. Label elements GHS-US labeling Hazard pictograms (GHS-US) : GHS04 Signal word (GHS-US) : WARNING Hazard statements (GHS-US) : H280 - CONTAINS GAS UNDER PRESSURE; MAY EXPLODE IF HEATED OSHA-H01 - MAY DISPLACE OXYGEN AND CAUSE RAPID SUFFOCATION Precautionary statements (GHS-US) : P202 - Do not handle until all safety precautions have been read and understood P271+P403 - Use and store only outdoors or in a well-ventilated place CGA-PG05 - Use a back flow preventive device in the piping CGA-PG10 - Use only with equipment rated for cylinder pressure CGA-PG06 - Close valve after each use and when empty CGA-PG02 - Protect from sunlight when ambient temperature exceeds 52°C (125°F) 2.3.
    [Show full text]
  • Lung Ventilation - Xenon
    Lung Ventilation - Xenon Special Instructions Patients with severe dyspnea may not be able to tolerate this examination. To be performed only at UNMH. Radiopharmaceutical: Xe-133 gas Dose (Adult/Pediatric): Refer to Nuclear Medicine Dose Chart Route of Administration: Inhalation from a Xe-133 gas delivery system. Patient Preparation: None. Equipment Setup: Gamma Camera: ZOOM as appropriate for small children Collimator: Orbiter: LEAP SPECT-CT/ECAM/Evo/Symbia E: High resolution Computer setup: • Static acquisition • 128 x 128 matrix • Zoom 1.0 (greater for small children)—ensure that the lungs fill a significant portion of the detector for small patients • 10 sec/image for inspiration • 30 sec/image for all other images Patient Positioning: Orbiter: • Seated upright on a stool (preferred) with the detector posterior to the patient. Supine if necessary All others: • Supine Procedure: • If the patient is able to sit upright on a stool for the examination, perform the ventilation portion of the examination on the Orbiter if available. • Before beginning the study, explain the breathing maneuvers required; the patient should rehearse these maneuvers. • Place the mask on the patient and ensure that it fits snugly. • Inspiration (Single-breath) Image: • Instruct the patient to exhale completely and then to take a deep breath as the Xe-133 gas flows in. • The patient should hold his/her breath for 10 sec (if possible) while posterior (and anterior if on a dual-headed camera) imaging is performed. Revised 2017-01 Lung Ventilation - Xenon (continued) • Equilibrium (Rebreathing/Wash-in) Images: • The patient should then breathe normally for 3 images (90 seconds).
    [Show full text]
  • Life Sciences in Utah Read
    EDCUTAH INDUSTRY PROFILE | FY 18-19 LIFE SCIENCES IN UTAH MAJOR UNIVERSITIES AND COLLEGES MAJOR EMPLOYERS ON THE COVER 1 Utah State University 4 Westminster College 6 Utah Valley University 9 Dixie State University 1 Paragon Medical Edwards Lifesciences Sapien 3 Heart Valve 2 Weber State University 5 Salt Lake 7 Brigham Young University 10 Rocky Vista University Community College 2 USU Research The Edwards Sapien 3 Transcatheter Heart Valve is changing 3 University of Utah 8 Southern Utah University Foundation the world of aortic stenosis therapy. In 2016 the Sapien 3 3 Fresenius USA received FDA approval for expanded use in the treatment of Manufacturing 4 Allergan intermediate-risk patients. The valve has the highest survival (formerly Actavis) rate ever reported in a TAVI clinical trial. 5 ARUP Laboratories LOGAN 6 Bard Access Systems 1 1 1 2 7 BioFire Diagnostics 8 Blackrock Microsystem 9 Biomerics 10 Clinical OGDEN Innovations 2 2 3 11 GE Healthcare 4 12 Great Basin 3 4 A 3 Scientific 4 SALT LAKE CITY 13 ICU Medical 5 A 6 14 Lineagen B 15 Myriad Genetic 4 Laboratories C 16 Nelson Laboratories 5 34 17 Otto Bock PROVO Healthcare 6 7 18 Pra Health Personalized Medicine, Medical Devices, Sciences 19 Recursion Pharmaceuticals 20 Sorenson World Class Research Genomics 21 Stryker Industry • In 2015, Utah’s post-performance tax incentives 22 Teva Pharma • Utah is proud to be home to companies like Merit facilitated nearly 25,000 new jobs and more than ceuticals Industries, (formerly Anesta, Medical Systems, BD (Becton Dickinson), Edwards $65M in new state revenue.
    [Show full text]
  • Thermo Fisher Scientific Inc. 168 Third Avenue Waltham, Massachusetts 02451, U.S.A
    Thermo Fisher Scientific Inc. 168 Third Avenue Waltham, Massachusetts 02451, U.S.A. THERMO FISHER SCIENTIFIC INC. 2007 EMPLOYEES' STOCK PURCHASE PLAN AS AMENDED AND RESTATED (THE "ESPP") Prospectus for the employees of certain European Economic Area ("EEA") subsidiaries of Thermo Fisher Scientific Inc., subject to the applicable legislation in each country Pursuant to articles L. 412-1 and L. 621-8 of the Code monétaire et financier and its General Regulation, in particular articles 211-1 to 216-1 thereof, the Autorité des marchés financiers ("AMF") has attached visa number 18-540 dated November 28, 2018, onto this prospectus. This prospectus was established by the issuer and incurs the responsibility of its signatories. The visa, pursuant to the provisions of Article L. 621-8-1-I of the Code monétaire et financier, was granted after the AMF verified that the document is complete and comprehensible, and that the information it contains is consistent. The visa represents neither the approval of the worthiness of the operation nor the authentication of the financial and accounting information presented. This prospectus will be made available in printed form to employees of the EEA subsidiaries of Thermo Fisher Scientific Inc. based in countries in which an offering under the ESPP is considered a public offering, subject to the applicable legislation in each country, at the respective head offices of their employers. In addition, this prospectus along with summary translations (as applicable) will be posted on Thermo Fisher Scientific Inc.’s intranet and free copies will be available to the employees upon request by contacting the human resources departments of their employers.
    [Show full text]
  • Corporate Social Responsibility
    2016 REPORT Corporate Social Responsibility Discover more at thermofisher.com/csr Thermo Fisher Scientific is the world leader in serving science, We have one Mission: generating $18 billion in annual revenue. Customers worldwide trust to enable our customers the products and solutions available through our premier brands to help them accelerate innovation and enhance productivity. to make the world healthier, cleaner and safer. Together, we are making a difference in the world. Letter from our CEO I am incredibly proud of the work we do at Thermo Fisher Scientific to fulfill our Mission: to enable our customers to make the world healthier, cleaner and safer. We have an extraordinary team of colleagues around the world who are committed to partnering with our customers to help them be successful. Whether they are developing cures for cancer, protecting the environment or making sure our food is safe, our customers look to us for solutions to some of the greatest challenges of this century. The way we approach our work is grounded by our 4i Values of Integrity, Intensity, Innovation and Involvement. These values guide our interactions with our customers and within the company, creating a culture where diverse perspectives are not only accepted, Marc N. Casper but also encouraged. Our colleagues are empowered to make a difference so they can President and CEO fulfill our Mission and their own career aspirations – which is the foundation of our success. Business sustainability We continually pursue new technology innovations and streamline our processes to ensure we are This corporate social responsibility (CSR) report highlights our key initiatives within the three pillars of our CSR strategy: business sustainability, employee involvement and philanthropic giving.
    [Show full text]
  • Our Mission in Action
    434105 QX9_Thermo Fisher 8.25 x 11 Grid 7/3/13 9:32 PM Page COV1 Our mission in action 2012 CORPORATE SOCIAL RESPONSIBILITY REPORT 434105 QX9_Thermo Fisher 8.25 x 11 Grid 7/1/13 11:20 AM Page COV2 We enable our customers to make the world healthier, cleaner and safer. CONTENTS Page 1 CEO Message Page 2 CSR Approach Page 3 About Thermo Fisher Scientific Page 6 Dedicated to Discovery Our Business Page 10 Making Connections, Creating Value Our Employees Page 13 Inspiring Education Our Philanthropy Page 18 Our Report Page 19 Global Reporting Initiative Index 434105 QX9_Thermo Fisher 8.25 x 11 Grid 7/1/13 11:20 AM Page 1 From Our CEO Thermo Fisher Scientific is the world leader in serving science. Our mission — to enable our customers to make the world healthier, cleaner and safer — perfectly captures our commitment to corporate social responsibility and sustainable growth. Globally, we provide state-of-the-art products and services that help our customers meet their own goals for sustainable growth, from specialty diagnostic tests to improve patient care, to air-quality systems that monitor stack emissions, to meters that ensure the safety of our drinking water. During 2012, we launched a number of innovative new products that improve healthcare and the environment, including: • Breakthrough advances in spectroscopy that help research scientists improve efficiency during experiments and accelerate results, • Continuous particulate monitors that measure microscopic airborne particles to assess the quality of the air we breathe, and • Bioprocessing media and systems to help biotech companies develop vaccines that dramatically reduce illness, especially among children.
    [Show full text]